M. Markowitz

发表

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

A. Trkola, J. Moore, D. Ho, 1999, The Journal of clinical investigation.

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

A. Perelson, D. Ho, M. Markowitz, 1995, Nature.

HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

A. Perelson, D. Ho, M. Markowitz, 1996, Science.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

D. Ho, M. Markowitz, J. Leonard, 1996, Nature Medicine.

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

A. Perelson, G. Learn, B. Korber, 2009, The Journal of experimental medicine.

Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10

H. Katinger, T. Wrin, C. Petropoulos, 2004, Journal of Virology.

Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.

Ruy M Ribeiro, Alan S Perelson, A. Perelson, 2004, Mathematical biosciences.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

A. Perelson, B. Korber, D. Ho, 1999, The New England journal of medicine.

Decay characteristics of HIV-1-infected compartments during combination therapy

Alan S. Perelson, A. Perelson, D. Ho, 1997, Nature.

A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo

Alan S. Perelson, A. Perelson, D. Ho, 2003, Journal of Virology.

Track A Basic Science

S. Sugden, D. Hazuda, F. Pereyra, 2012, Journal of the International AIDS Society.

Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor

D. Ho, M. Markowitz, H. Mo, 1997, Antimicrobial agents and chemotherapy.

Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors

M. Markowitz, D. Boden, Daniel Boden, 1998, Antimicrobial Agents and Chemotherapy.

Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

M A Nowak, M. Nowak, D. Ho, 1998, Science.

Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract

Christine Hogan, Amir Horowitz, Klara Tenner-Racz, 2004, The Journal of experimental medicine.

5′ Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice

M. Markowitz, D. Kaufmann, Xueling Wu, 2018, Front. Immunol..

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

D. Ho, M. Markowitz, H. Mo, 1996, Antimicrobial agents and chemotherapy.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

R Brookmeyer, R. Siliciano, J. Margolick, 1997, Science.

High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy

M. Markowitz, P. Halkitis, K. Meyers, 2014, PloS one.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope

M. Markowitz, X. Kong, Teresa H. Evering, 2014, Retrovirology.

Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection

Jörn E. Schmitz, Joseph J. Eron, Barton F. Haynes, 2009, PLoS medicine.

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

T. Kepler, X. Chen, M. Egholm, 2011, The Journal of experimental medicine.

Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure

M. Markowitz, H. Salomón, P. Cahn, 2002, Journal of Virology.

The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy

A. Perelson, J. Percus, D. Ho, 2003, Bulletin of mathematical biology.

Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic

M. Carrington, B. Walker, J. Fuchs, 2014, PLoS genetics.

Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection

A. Perelson, D. Ho, D. Follmann, 2004, Journal of Virology.

Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic

M. Carrington, B. Walker, J. Fuchs, 2015, Journal of Virology.

Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1

M. Markowitz, M. Sobieszczyk, Tristan D. McPherson, 2018, Expert opinion on investigational drugs.

Drug Resistance Mutation Frequency of Single-Genome Amplification-Derived HIV-1 Polymerase Genomes in the Cerebrospinal Fluid and Plasma of HIV-1-Infected Individuals under Nonsuppressive Therapy

M. Markowitz, H. Mohri, Teresa H. Evering, 2020, Journal of Virology.

Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010 .

Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens: 80-Week Data From a Phase 2 Study

M. Markowitz, H. Valdez, D. Mayers, 2007, Journal of acquired immune deficiency syndromes.

Early immune adaptation in HIV-1 revealed by population-level approaches

Todd M. Allen, H. Jessen, T. Allen, 2014, Retrovirology.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b

K. White, M. Markowitz, H. Stellbrink, 2014, The Lancet. Infectious diseases.

Transmitted Drug Resistance and Phylogenetic Relationships Among Acute and Early HIV-1–Infected Individuals in New York City

M. Markowitz, M. Lamar, S. Mehandru, 2012, Journal of acquired immune deficiency syndromes.

The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection.

M. Markowitz, P. Rácz, S. Mehandru, 2005, The Journal of allergy and clinical immunology.

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data

H. Katinger, M. Markowitz, G. Stiegler, 2007, AIDS.

Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection

Todd M. Allen, D. Heckerman, E. Rosenberg, 2010, Journal of Virology.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeﬁciency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, X. Jin, 2002 .

Evidence of dysregulation of dendritic cells in primary HIV infection

K. Shianna, J. Fellay, M. Markowitz, 2010, Blood.

Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1

M. Markowitz, B. Greenbaum, O. Schwartz, 2022, iScience.

Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection

David Heckerman, Anthony D. Kelleher, Zabrina L. Brumme, 2008, Journal of Virology.

Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection

M. Markowitz, P. Rácz, H. Mohri, 2012, PLoS pathogens.

DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes

M. Carrington, R. Steinman, M. Nussenzweig, 2007, Proceedings of the National Academy of Sciences.

Title: Once-weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques from Intrarectal SHIV109CP3 Challenge.

D. Hazuda, M. Markowitz, A. Gettie, 2020, Journal of Infectious Diseases.

Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251

D. Ho, M. Markowitz, A. Gettie, 2017, AIDS.

Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection.

M. Markowitz, S. Vasan, M. Tsuji, 2007, International immunology.

Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections

Feng Gao, Bette Korber, Tongye Shen, 2011, PLoS pathogens.

Anal Dysplasia in Human Immunodeficiency Virus-Infected Men Who Have Sex With Men With Sexually Acquired Early Hepatitis C Virus Infection

S. Haber, M. Markowitz, D. Fierer, 2019, Open forum infectious diseases.

Correction: Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 Infection

M. Markowitz, P. Rácz, H. Mohri, 2006, PLoS Medicine.

Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1.

M. Markowitz, S. Mehandru, N. Kreiswirth, 2009, The Journal of infectious diseases.

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.

D. Ho, A. Hurley, M. Markowitz, 1995, The New England journal of medicine.

An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes

D. Ho, D. Nixon, S. Bonhoeffer, 2000, Molecular medicine.

Human Immunodeficiency Virus Type 1 Induces Persistent Changes in Mucosal and Blood γδ T Cells despite Suppressive Therapy

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of Virology.

4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor

S. Sarafianos, M. Markowitz, 2018, Current opinion in HIV and AIDS.

Measuring Recent Thymic Emigrants in Blood of Normal and HIV-1–Infected Individuals before and after Effective Therapy

Paul Palumbo, D. Ho, Steven Wolinsky, 1999, The Journal of experimental medicine.

Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.

M. Markowitz, J. Grobler, 2019, Current opinion in HIV and AIDS.

Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.

M. Markowitz, A. Shet, 2006, Current opinion in investigational drugs.

Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience

Christine Hogan, M. Markowitz, V. Simon, 2006, Journal of acquired immune deficiency syndromes.

GSK1265744 Demonstrates Robust In Vitro Activity Against Various Clades of HIV-1

M. Markowitz, H. Mohri, W. Spreen, 2015, Journal of acquired immune deficiency syndromes.

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

Sebastian Bonhoeffer, Alan S Perelson, John E Mittler, 1999, The Lancet.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

D. Ho, A. Hurley, M. Markowitz, 1998, The Journal of infectious diseases.

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2015, Science Translational Medicine.

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2014, Science.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

R. Haubrich, B. Clotet, M. Markowitz, 2007, The Lancet.

HIV-1 drug resistance in newly infected individuals.

Y. Cao, L. Zhang, A. Hurley, 1999, JAMA.

Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial

M. Markowitz, H. Mohri, N. Bhardwaj, 2019, Front. Immunol..

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

D. R. Kuritzkes, Y. Cao, D. Kuritzkes, 1998, Antimicrobial Agents and Chemotherapy.

Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 Infection

M. Markowitz, P. Rácz, H. Mohri, 2006, PLoS medicine.

Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy

D. Ho, L. Zhang, A. Hurley, 1999, Journal of Virology.

Effective Antiretroviral Therapy 1-Infected Individuals on Prolonged Human Immunodeficiency Virus Type Beacons To Detect Virus Replication in Use of Real-Time PCR and Molecular

L. Zhang, A. Hurley, M. Markowitz, 1999 .

Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.

D. Ho, Y. Cao, M. Markowitz, 1997, Virology.

Towards an HIV cure: a global scientific strategy

M. Lederman, J. Mullins, A. Telenti, 2012, Nature Reviews Immunology.

Compartmentalization of Surface Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 during Acute and Chronic Infection

D. Ho, M. Markowitz, Linqi Zhang, 2002, Journal of Virology.

Viral Envelope Is a Major Determinant of Enhanced Fitness of a Multidrug-Resistant HIV-1 Variant

M. Markowitz, H. Mohri, N. Prada, 2015, Journal of acquired immune deficiency syndromes.

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

D. Ho, X. Jin, L. Zhang, 2000, The Journal of clinical investigation.

Rapid, Transient Changes at theenv Locus of Plasma Human Immunodeficiency Virus Type 1 Populations during the Emergence of Protease Inhibitor Resistance

M. Markowitz, E. Delwart, Heng Pan, 1998, Journal of Virology.

Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia

E. Rosenberg, H. Jessen, F. Pereyra, 2014, Journal of Virology.

Early Control of HIV-1 Viremia Impaired Nef Function Is Associated with

E. Rosenberg, H. Jessen, F. Pereyra, 2014 .

Compensated CD8 Escape Mutations Transmission and Long-Term Stability of

E. Rosenberg, B. Walker, Yaoyu E. Wang, 2012 .

Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers

E. Rosenberg, H. Jessen, F. Pereyra, 2010, Journal of Virology.

Transmission and Long-Term Stability of Compensated CD8 Escape Mutations

Todd M. Allen, E. Rosenberg, H. Jessen, 2008, Journal of Virology.

Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective.

M. Markowitz, M. Louie, 2002, Antiviral research.

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

J. Moore, D. Ho, J. Binley, 1999, The Journal of infectious diseases.

Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins.

D. Burton, D. Montefiori, P. Bieniasz, 2014, Cell host & microbe.

Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report

D. Ho, T. Wrin, C. Petropoulos, 2005, The Lancet.

Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy

Alan S. Perelson, Ruy M. Ribeiro, L. Weinberger, 2001, The Journal of experimental medicine.

Elite Suppressor–Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics

R. Siliciano, T. Chou, M. Markowitz, 2009, PLoS pathogens.

Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses in Subjects Treated Early after Infection

G. M. Ortiz, D. Nixon, M. Markowitz, 2002, Journal of Virology.

Should We Treat Acute HIV Infection?

M. Markowitz, Martin Markowitz, Meagan O’Brien, 2012, Current HIV/AIDS Reports.

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men

Alan S. Perelson, Hui Li, Tanmoy Bhattacharya, 2010, PLoS pathogens.

Erratum: Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection (PloS Medicine 3,12 DOI:10.1371/journal.pmed. 0030484)

M. Markowitz, P. Rácz, H. Mohri, 2006 .

Mechanisms of Gastrointestinal CD4+ T-Cell Depletion during Acuteand Early Human Immunodeficiency Virus Type 1 Infection

M. Markowitz, P. Rácz, H. Mohri, 2006, Journal of Virology.

Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy

M. Nowak, D. Ho, Y. Cao, 1999, Journal of Virology.

Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques

C. Cheng‐Mayer, M. Markowitz, Xueling Wu, 2016, Journal of Virology.

Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

M. Carrington, H. Katinger, T. Wrin, 2007, Journal of Virology.

Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

J. Moore, D. Ho, J. Binley, 1997, Journal of virology.

Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of virology.

Y-RNAs Lead an Endogenous Program of RIG-I Agonism Mobilized upon RNA Virus Infection and Targeted by HIV

M. Markowitz, B. Greenbaum, O. Schwartz, 2019, bioRxiv.

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

S. Haber, M. Markowitz, D. Fierer, 2018, Open forum infectious diseases.

Early immune adaptation in HIV-1 revealed by population-level approaches

Todd M. Allen, H. Jessen, M. Carrington, 2014, Retrovirology.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

Yang Song, Soe Than, Martin Ho, 2010, PloS one.

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

A. Perelson, D. Ho, A. Hurley, 2002, The Journal of infectious diseases.

Brief Report: The Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune Activation

M. Markowitz, S. Mehandru, S. Deren, 2017, Journal of acquired immune deficiency syndromes.

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype.

D. Levy, M. Markowitz, L. Rolnitzky, 2011, The Journal of clinical investigation.

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

A. Trkola, D. Richman, J. Moore, 2000, The Journal of infectious diseases.

HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy

D. Ho, J. Binley, John P. Moore, 1998, The Journal of experimental medicine.

Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China

M. Markowitz, Hao Wu, Lei Zhang, 2018, AIDS and Behavior.

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

Alan S. Perelson, John E. Mittler, Catherine A. Macken, 2000, Nature Medicine.

Induction With Abacavir/Lamivudine/Zidovudine Plus Efavirenz for 48 Weeks Followed by 48-Week Maintenance With Abacavir/Lamivudine/Zidovudine Alone in Antiretroviral-Naive HIV-1-Infected Patients

M. Markowitz, E. Dejesus, M. Shaefer, 2005, Journal of acquired immune deficiency syndromes.

Behavioural, Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug Users

M. Markowitz, M. Lamar, S. Mehandru, 2015, Journal of addiction research & therapy.

Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection

T. Wrin, M. Markowitz, N. Parkin, 2003, Journal of Virology.

Jeroen Primary Infection Virus Type 1 Variants Isolated during Drug-Resistant Human Immunodeficiency Infectivity and Replication Capacity of

T. Wrin, M. Markowitz, N. Parkin, 2003 .

Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.

M. Markowitz, R. Grant, H. Mohri, 2017, Journal of acquired immune deficiency syndromes.

Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.

M. Markowitz, R. Grant, H. Mohri, 2017, Journal of acquired immune deficiency syndromes.

Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical Course

M. Carrington, F. Duh, M. Markowitz, 2008, Journal of acquired immune deficiency syndromes.

Extending access with long-acting antiretroviral therapy: the next advance in HIV-1 therapeutics and prevention.

M. Markowitz, Kathrine Meyers, 2015, Current opinion in HIV and AIDS.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, A. Hurley, 2002, Journal of Virology.

Highly Active Antiretroviral Therapy 1-Infected Patients Treated with Prolonged Human Immunodeficiency Virus Type vCP 1452 and Recombinant gp 160 in Newly Safety and Immunogenicity of ALVAC

D. Ho, J. Binley, A. Hurley, 2002 .

Challenges in Recruiting People Who Use Drugs for HIV-Related Biomedical Research: Perspectives from the Field.

M. Markowitz, M. Lamar, S. Mehandru, 2016, AIDS patient care and STDs.

Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now.

M. Markowitz, 2019, Current opinion in HIV and AIDS.

Andrews 1..9

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2015 .

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

D. Ho, T. Bhat, M. Markowitz, 1995, Journal of virology.

Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy

John M. Leonard, P. Scott Eastman, Mickey Urdea, 1998, Journal of Virology.

Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.

D. Ho, C. Petropoulos, M. Markowitz, 1999, The Journal of infectious diseases.

To Promote Circumcision as a Preventive Measure against Human Immunodeficiency Virus Transmission Is Irresponsible

D. Ho, C. Petropoulos, M. Markowitz, 2010 .

Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection

J. Corbeil, J. Margolick, D. Richman, 2004, Journal of Virology.

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy.

D. Ho, Y. Cao, D. Nixon, 1999, Immunology letters.

Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy

A. Perelson, J. Mittler, M. Markowitz, 2001, Antimicrobial Agents and Chemotherapy.

A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1–Infected Individuals

M. Markowitz, H. Mohri, S. Palmer, 2014, Journal of acquired immune deficiency syndromes.

Viral Blip Dynamics during Highly Active Antiretroviral Therapy

Alan S. Perelson, Christine Hogan, A. Perelson, 2003, Journal of Virology.

The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.

J. Moore, J. Binley, G. M. Ortiz, 2000, The Journal of infectious diseases.

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection

E. Rosenberg, S. Little, D. Kuritzkes, 2010, PLoS ONE.

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

D. Hazuda, F. Vaida, M. Markowitz, 2009, Antimicrobial Agents and Chemotherapy.

Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection

M. Markowitz, C. Pace, 2015, Current opinion in HIV and AIDS.

Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.

J. Moore, A. Hurley, M. Markowitz, 2000, AIDS research and human retroviruses.

In Vitro Characterization of Multidrug-Resistant HIV-1 Isolates From a Recently Infected Patient Associated With Dual Tropism and Rapid Disease Progression

M. Markowitz, H. Mohri, 2008, Journal of acquired immune deficiency syndromes.

Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection

M. Markowitz, A. Applebaum, D. Garmon, 2016, AIDS.

Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.

M. Markowitz, S. Mehandru, S. Deren, 2016, The Journal of infectious diseases.

Mechanisms of Gastrointestinal CD4 (cid:1) T-Cell Depletion during Acute and Early Human Immunodeﬁciency Virus Type 1 Infection (cid:1)

M. Markowitz, P. Rácz, H. Mohri, 2006 .

All known cross-reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time

B. Haynes, D. Dimitrov, M. Markowitz, 2008 .

Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

M. Markowitz, R. Grant, P. Defechereux, 2018, AIDS and Behavior.

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

D. Ho, M. Markowitz, S. Gulnik, 1996, AIDS research and human retroviruses.

Estimates of Intracellular Delay and Average Drug Efficacy from Viral Load Data of HIV-Infected Individuals under Antiretroviral Therapy

Alan S Perelson, A. Perelson, D. Ho, 2004, Antiviral therapy.